IFN-gamma-release assays in the management of tuberculosis.

New blood tests for TB are now available. One measures the release of IFN-gamma and the other estimates the number of cells secreting IFN-gamma after stimulation with antigens from Mycobacterium tuberculosis. The choice of antigens (esat-6 and cfp-10) is intended to distinguish TB infection from Bacille Calmette-Guerin vaccination. Tests differ in lymphocyte numbers, the use of an additional antigen (TB7.7 - Rv2654) and sensitivity in concurrent HIV infection. Their role in the routine diagnosis of TB is limited. In latent TB infection, the new tests correlate better with exposure to TB. However, the time course of the immune response, the significance of negative tests, conversions from positive to negative and vice versa and their value in predicting who will develop TB are not yet known. Prospective studies of these tests are needed to establish their practical value rather than theoretical role in latent TB infection. Cohorts of both immunocompetent and immunosuppressed subjects who may develop active disease should be examined.